Medidata’s new cloud system will simplify how providers, investigators collect data

New York-based Medidata, a cloud-based systems provider, has launched a new program that will allow easy integration of healthcare data from electronic health records (EHRs), electronic medical records (EMRs) and clinical trial electronic source data into one single platform, the Medidata Clinical Cloud.

The initiative, branded the eConnect Partner Program, is designed to help organize and keep track of the many digital documents providers need when treating patients, according to a statement from the company.

“Pharmaceutical, biotech and medical device companies are increasingly looking for technologies to gather more and better patient data,” said Medidata’s president Glen de Vries in a statement. “However, a key concern is the increasing burden on investigative sites, currently tasked with using disparate systems for different clinical trials in addition to the systems needed to manage their medical practices and record data from patients who are not participating in research studies.”

The eConnect program will simplify day-to-day operations and workflows by eliminating the need for staff to repeatedly enter the same data into multiple systems. Right now, investigative sites are using an average of 10 different systems to collect data for clinical trials, according to CenterWatch. The system will also resolve transcription errors.

“eConnect is the first commercially available program to alleviate ‘swivel chair interoperability,’ no matter what type of eSource system clinical trial sites use—whether it's their own, a sponsor-provided technology or an EHR or EMR integration,” de Vries said. “The flexibility our program provides will make it easier for sponsors to work with investigative sites that have the right therapeutic expertise while supporting broader efforts to drive their long-term retention in clinical research programs.”

Katherine Davis,

Senior Writer

As a Senior Writer for TriMed Media Group, Katherine primarily focuses on producing news stories, Q&As and features for Cardiovascular Business. She reports on several facets of the cardiology industry, including emerging technology, new clinical trials and findings, and quality initiatives among providers. She is based out of TriMed's Chicago office and holds a bachelor's degree in journalism from Columbia College Chicago. Her work has appeared in Modern Healthcare, Crain's Chicago Business and The Detroit News. She joined TriMed in 2016.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.